Review: four years of cat-and-mouse chemistry as manufacturers evade China's synthetic cannabinoid ban | Research

The takeaway

Since China banned seven major synthetic cannabinoid scaffolds in 2021, manufacturers have used at least six distinct chemical strategies to create novel compounds that circumvent the legislation, including a concerning DIY synthesis approach that lets users convert legal precursors into banned substances.

Drug policy researchers, toxicologists, harm reduction workers, and anyone concerned about synthetic cannabinoid trends.

DIY synthesis approach lets users convert legal precursors into banned, potent synthetic cannabinoids

What the researchers found

Ban-evading strategies included: alternative core structures (oxoindolins, oxopyridone, benzoate), linker replacement (acetamide instead of carboxamide), positional switching on conventional cores, adding or removing substituents (bromination, tail-less compounds), and a do-it-yourself synthesis approach where users convert legal tail-less precursors into banned potent SCRAs.

Why it matters

China's 2021 ban was one of the most sweeping generic drug scheduling efforts ever attempted. This review documents how four years of manufacturer innovation have already undermined it, creating a flood of novel compounds with unknown potency, toxicity, and metabolic profiles that challenge both forensic detection and emergency medicine.

The numbers in context

7 SCRA scaffolds covered by the 2021 Chinese ban. At least 6 distinct chemical evasion strategies documented. Named compounds include OXIZIDs, CH-FUBBMPDORA, NMDMSB, ADB-FUBIATA, 5F-3,5-AB-PFUPPYCA, ADB-INACA, and ADB-5'Br-BUTINACA, among others. Period covered: mid-2021 to mid-2025.

How the study worked

The review compiled and analyzed all synthetic cannabinoid receptor agonists that emerged between mid-2021 and mid-2025 in response to China's generic ban. The authors categorized ban-evading strategies, discussed detection and metabolic profiling challenges, and presented first-published pharmacological data for some uncharacterized compounds.

What this study cannot tell us

The review focuses on compounds detected in forensic and analytical reports, which may not capture all novel SCRAs in circulation. Pharmacological characterization is incomplete for many compounds. The review does not quantify health outcomes or prevalence of use for individual compounds.

How to read the evidence

Comprehensive review of post-ban chemical landscape with original pharmacological data for some compounds, drawing on forensic, analytical, and regulatory sources.

When this study was published

Published in 2025, covering mid-2021 to mid-2025.

The bigger picture

The DIY synthesis approach is particularly alarming: if users can easily convert legal precursors into potent banned SCRAs, the entire concept of precursor scheduling may need rethinking. This cat-and-mouse dynamic between regulators and manufacturers shows no signs of stabilizing, and each new compound carries unknown risks.

Questions still open

Is generic scheduling fundamentally unable to keep pace with chemical innovation? Could international coordination on precursor chemicals be more effective? How many undetected novel SCRAs are currently circulating? Can rapid pharmacological screening keep pace with the rate of new compound emergence?

Common questions

What did China ban in 2021?

China enacted a generic ban covering seven common synthetic cannabinoid scaffolds (chemical backbone structures), attempting to ban entire classes of compounds rather than individual molecules.

Why is the DIY synthesis approach concerning?

It allows users or intermediate suppliers to buy legal, unscheduled precursor compounds and easily convert them into potent banned SCRAs, effectively bypassing both the ban and supply chain controls.

Are these new compounds more dangerous?

Potentially. Many have unknown potency, toxicity, and metabolic profiles. Some are structurally novel enough that standard drug tests cannot detect them, and emergency physicians may not recognize poisoning patterns.

Read the original research

Outsmarting generic legislation: 4 years into the cat-and-mouse game of the synthetic cannabinoid receptor agonist market since the Chinese ban in 2021.

Archives of toxicology, 99(12), 4757-4784

View on PubMed ↗Publisher’s paper ↗

Citation

Deventer, Marie H; Stove, Christophe P. (2025). Outsmarting generic legislation: 4 years into the cat-and-mouse game of the synthetic cannabinoid receptor agonist market since the Chinese ban in 2021.. Archives of toxicology, 99(12), 4757-4784. https://doi.org/10.1007/s00204-025-04191-0